A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Posts by this author

WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA

   57
WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA

STA Pharmaceutical, a WuXi AppTec Company (WuXi STA), announces their partner Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib. Under the Marketing Authorization Holder (MAH) policy, WuXi STA provided an integrated and end-to-end support including drug substance, amorphous solid dispersion, tablet and packaging for this product.  Just a couple months ago, with four WuXi STA’s sites inspected at the same time, WuXi STA successfully passed the pre-approval inspection (PAI) for Orelabrutinib from NMPA. 

Vaccine Nationalism, CDMO expansion, AMR and Dual sourcing predicted in 2021 According to New CPhI Report

   201
Vaccine Nationalism, CDMO expansion, AMR and Dual sourcing predicted in 2021 According to New CPhI Report

A new report from CPhI explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies.

The report – which summarises expert analysis into 12 key findings – foresees a particularly positive outlook for the pharma manufacturing supply chain, as a result of the demand for increased second source contingencies, alongside the huge scale-up of vaccine capacity currently underway. A consequence of which is likely to encourage expansion across the contract services sector for all product classes and therapy areas.

ATMPS advanced therapy blockchain platform has successful testing with NHS partners

   328

New ‘blockchain ecosystem’ has potential to track, from vein-to-vein, advanced therapies

19 October, 2020: ATMPS Ltd – a spinout of FarmaTrust announces that its Hataali blockchain platform has been successfully tested with University Hospitals Birmingham NHS Foundation Trust’s system interface. Data interoperability was shown to be possible, rendering the Hataali platform as the world’s first blockchain solution for advanced therapeutic medicinal products.